A practical overview of aromatase inhibitors.
Anticancer Res
; 25(3c): 2497-502, 2005.
Article
en En
| MEDLINE
| ID: mdl-16080483
ABSTRACT
Tamoxifen has been the standard adjuvant therapy for patients with breast cancer for several decades. Various recently completed adjuvant trials using aromatase inhibitors have shown the superiority of these agents over Tamoxifen or placebo, when used in post-menopausal women. The results from these trials present a challenging situation for practicing oncologists with regards to the choice, duration, sequence of therapy, follow-up and side-effects of aromatase inhibitors. Various management issues from a practical angle for oncologists are discussed for the effective use of these agents, with an evidence-based approach.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Inhibidores de la Aromatasa
Tipo de estudio:
Clinical_trials
Límite:
Female
/
Humans
Idioma:
En
Revista:
Anticancer Res
Año:
2005
Tipo del documento:
Article
País de afiliación:
Canadá